- Home
- SONM vs MTVA Comparison
SONM vs MTVA Comparison
Compare SONM & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONM
- MTVA
- Stock Information
- Founded
- SONM 1999
- MTVA 2014
- Country
- SONM United States
- MTVA United States
- Employees
- SONM N/A
- MTVA N/A
- Industry
- SONM Telecommunications Equipment
- MTVA
- Sector
- SONM Telecommunications
- MTVA
- Exchange
- SONM Nasdaq
- MTVA NYSE
- Market Cap
- SONM 12.6M
- MTVA 14.3M
- IPO Year
- SONM 2019
- MTVA N/A
- Fundamental
- Price
- SONM $0.73
- MTVA $0.71
- Analyst Decision
- SONM
- MTVA Strong Buy
- Analyst Count
- SONM 0
- MTVA 2
- Target Price
- SONM N/A
- MTVA $7.50
- AVG Volume (30 Days)
- SONM 1.9M
- MTVA 64.8K
- Earning Date
- SONM 08-08-2025
- MTVA 08-13-2025
- Dividend Yield
- SONM N/A
- MTVA N/A
- EPS Growth
- SONM N/A
- MTVA N/A
- EPS
- SONM N/A
- MTVA N/A
- Revenue
- SONM $58,243,000.00
- MTVA N/A
- Revenue This Year
- SONM $127.68
- MTVA N/A
- Revenue Next Year
- SONM N/A
- MTVA N/A
- P/E Ratio
- SONM N/A
- MTVA N/A
- Revenue Growth
- SONM N/A
- MTVA N/A
- 52 Week Low
- SONM $0.60
- MTVA $0.60
- 52 Week High
- SONM $6.38
- MTVA $4.36
- Technical
- Relative Strength Index (RSI)
- SONM 43.46
- MTVA N/A
- Support Level
- SONM $0.67
- MTVA N/A
- Resistance Level
- SONM $0.77
- MTVA N/A
- Average True Range (ATR)
- SONM 0.05
- MTVA 0.00
- MACD
- SONM 0.01
- MTVA 0.00
- Stochastic Oscillator
- SONM 47.91
- MTVA 0.00
About SONM Sonim Technologies Inc.
Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.